ConcertAI’s TeraRecon adds AI-based Oncology Contouring Capabilities into the Eureka Clinical AI Platform with Coreline Soft Partnership

The Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now provides clinicians with the state-of-the-art artificial intelligence and deep learning technology necessary to automatically detect and segment lung nodules and calculate coronary artery calcification through solutions from Coreline Soft.

Coreline Soft offers artificial intelligence algorithms for use in medical imaging, specializing in heart and lung imaging. Their AVIEW CAC algorithm is designed for calcium scoring in the chest and cardiac areas and can be used to automatically segment the heart and surrounding structures and accurately analyze calcified plaques in coronary arteries. Their AVIEW LCS+ algorithm is designed for cancer screening in the chest area and can be used to detect lung nodules, measure emphysema index, and calculate CAC on non-gated scans. Both algorithms are designed to be used with CT scans.

AiThority: How Generative AI is Transforming Audio Content

“With the addition of Coreline’s calcium scoring technologies on Eureka Clinical AI, we’ll be able to help clinicians automatically analyze and quantify the image data obtained from a single chest computed tomography (CT) scan and provide information about lung cancer and cardiovascular diseases at the same time, increasing accuracy, efficiency and supporting earlier diagnosis and treatment for patients,” said Dan McSweeney, President of TeraRecon.

“TeraRecon’s substantial global install base represents a significant and immediate distribution opportunity for the unique analysis capabilities of Coreline Soft’s oncology and cardiac solutions. We are thrilled to offer our solutions on the Eureka Clinical AI platform and to all healthcare providers needing these services in a streamlined and best-in-breed ecosystem that TeraRecon offers,” said Coreline Soft CEO Jinkook Kim.

Eureka Clinical AI is the leading AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. As the industry’s most broadly deployed platform, it is unique in that it is open to third-party AI algorithms, allowing consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can see results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management and coordinated care delivery.

Read: How AI NFTs Are Unlocking the Democratization of the Digital Economy

[To share your insights with us, please write to sghosh@martechseries.com]